Tag Archives: Eli Lilly
By Ben Comer | Published: December 7, 2011
Global headquarters may get the strategic ball rolling for a new drug launch, but Lilly’s affiliates are responsible for bringing home the bacon, according to a Lilly global brand director.
By Ben Comer | Published: August 16, 2011
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
By Ben Comer | Published: June 21, 2011
Can the management style known as Six Sigma help improve the probability of a drug’s commercial success, or do its black-belted acolytes punch holes in the creative process needed for innovative R&D discovery?
By Oriana Schwindt | Published: May 26, 2010
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
By Oriana Schwindt | Published: April 21, 2010
Eli Lilly announced its first quarter financial results on April 19. But even though the company trumpeted a global revenue growth rate of 9 percent—$5.49 billion, compared to Q1 2009’s $5.05 billion—net income fell 5 percent to $1.25 billion. Part of the blame for that 4 percent difference, the company said, lies with the passage of [...]